SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

NCT03645876 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to company decision

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: SHR-1210
DRUG: BP102
DRUG: oxaliplatin
DRUG: capecitabine

Sponsor

Jiangsu HengRui Medicine Co., Ltd.